Table 1.
The outcomes and physiological effects of microglial depletion in different disease conditions
| Depletion ways | Disease conditions | Outcomes | Physiological effects | References |
|---|---|---|---|---|
| CD11b‐HSVTK | EAE (MS) | Beneficial | Ameliorates clinical manifestations and reduces infiltrating cells | Heppner et al. (2005) |
| PLX5622 | EAE (MS) | Beneficial | Improves mobility by increasing mature oligodendrocytes | Nissen et al. (2018) |
| BLZ945 | Cuprizone model (MS) | Beneficial | Enhances remyelination in the striatum and cortex | Beckmann et al. (2018) |
| PLX3397 | Intracerebral hemorrhage | Beneficial | Attenuates neurological https://www.google.se/search?q=abnormalities&spell=1&sa=X&ved=0ahUKEwi38NK94bfYAhUMMJoKHSPtDHEQvwUIJCgA and brain edema | Li, Li, et al. (2017) |
| PLX5622 | Charcot–Marie‐tooth | Beneficial | Improves axonal integrity and muscle weakness | Klein et al. (2015) |
| PLX3397 | AD | Beneficial | Improves the spatial and emotional memory deficits | Sosna et al. (2018) |
| GW2580 | AD | Beneficial | Prevents the progression of AD pathology | Olmos‐Alonso et al. (2016) |
| PLX5622 | AD | Beneficial | Improves the hippocampal‐dependent tasks | Dagher et al. (2015) |
| PLX3397 | AD | Beneficial | Improves contextual memory deficits but not Aβ pathology | Spangenberg et al. (2016) |
| CX3CR1CreDTR | AD | Not clear | Leads to enlargement of Aβ plaques but not number of plaques | Zhao et al. (2017) |
| PLX3397 | AD | Beneficial | Inhibits the propagation of tau and reduces the excitability | Asai et al. (2015) |
| GW2580 | ALS | Beneficial | Attenuates motor neuron cell death and extends life expectancy | Martinez‐Muriana et al. (2016) |
| CD11b‐HSVTKmt | ALS | No effect | Has little effect on motor neuron degeneration and reflex scores | Gowing et al. (2008) |
| PLX3397 | ALS | Harmful | Reduces evoked compound muscle action potentials | Spiller et al. (2018) |
| PLX5622 | AUD | Beneficial | Enhances induction of anti‐inflammatory genes | Walter et al. (2017) |
| PLX5622 | Catatonia | Beneficial | Alleviates catatonic signs and reduces white matter inflammation | Janova et al. (2017) |
| PLX5622 | Radiation‐induced memory deficits | Beneficial | Prevents memory deficits by inhibiting monocyte accumulation | Feng et al. (2016) |
| PLX5622 | Radiation‐induced memory deficits | Beneficial | Attenuates microglial activation in the irradiated hippocampus and ameliorates radiation‐induced cognitive deficits | Acharya et al. (2016) |
| PLX5622 | Neuropathic pain | Beneficial | Alleviates both mechanical and cold allodynia | Lee et al. (2018) |
| LEC | Neuropathic pain | Beneficial | Reduces initiation rather not maintenance of neuropathic pain | Wang et al. (2018) |
| PLX3397 | Neuronal injury | Beneficial | Improves recovery by modulating inflammatory signals | Rice et al. (2015) |
| PLX5622 | POCD | Beneficial | Reduces hippocampal pro‐inflammatory cytokines and inhibits CCR2‐expressing cells infiltration | Feng et al. (2017) |
| PLX3397 | Cerebral ischemia | Harmful | Promotes leukocyte infiltration and exacerbates brain infarction | Jin et al. (2017) |
| PLX3397 | Cerebral ischemia | Harmful | Causes neuronal death and increases infarct size | Szalay et al. (2016) |
| PLX3397 | PD | Harmful | Increases MPTP neurotoxicity and augments neurodeficits | Yang et al. (2018) |
| PLX5622 | Coronavirus encephalitis | Harmful | Delays virus clearance and promotes immune cells infiltration | Wheeler et al. (2018) |
AUD = Alcohol use disorder; MS = Multiple sclerosis; EAE = experimental autoimmune encephalomyelitis; AD = Alzheimer's disease; ALS = Amyotrophic lateral sclerosis; PD = Parkinson's disease; MPTP = 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine; TDP43 = TAR DNA‐binding protein 43; LEC = Liposome‐encapsulated clodronate; POCD = Postoperative cognitive decline.